REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have been assigned an average rating of “Moderate Buy” from the twelve analysts that are currently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $35.27.

A number of analysts recently weighed in on RGNX shares. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Morgan Stanley reissued an “overweight” rating and set a $22.00 price objective on shares of REGENXBIO in a research note on Friday, November 15th. Raymond James reaffirmed an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. Royal Bank of Canada reiterated an “outperform” rating and issued a $35.00 price target on shares of REGENXBIO in a research report on Wednesday, December 11th. Finally, HC Wainwright cut their price objective on REGENXBIO from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Thursday, November 21st.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Redmile Group LLC boosted its stake in shares of REGENXBIO by 7.1% during the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock valued at $51,327,000 after buying an additional 323,100 shares during the period. Integral Health Asset Management LLC raised its holdings in shares of REGENXBIO by 25.0% during the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock worth $11,115,000 after acquiring an additional 190,000 shares in the last quarter. Millennium Management LLC raised its holdings in shares of REGENXBIO by 84.8% during the second quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company’s stock worth $3,586,000 after acquiring an additional 140,666 shares in the last quarter. Squarepoint Ops LLC boosted its position in REGENXBIO by 630.9% during the second quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock valued at $1,711,000 after purchasing an additional 126,249 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in REGENXBIO by 73.4% in the second quarter. Cubist Systematic Strategies LLC now owns 188,235 shares of the biotechnology company’s stock valued at $2,202,000 after purchasing an additional 79,655 shares in the last quarter. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Trading Down 9.4 %

Shares of NASDAQ RGNX opened at $7.51 on Monday. The firm has a 50-day moving average of $9.01 and a two-hundred day moving average of $10.68. The company has a market capitalization of $372.08 million, a price-to-earnings ratio of -1.49 and a beta of 1.28. REGENXBIO has a twelve month low of $7.14 and a twelve month high of $28.80.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.